Answers are grounded in this paper and cite their sources.
Background: Recently, early non-invasive identification of Ki-67 levels and histological subtypes in non-small cell lung cancer remains a significant obstacle. With the application of radiomics in cancer diagnosis and treatment, several researchers have investigated the accuracy of radiomics for non-invasive detection of Ki-67 levels and histological subtypes in lung cancer. Nonetheless, there is a dearth of systematic evidence. Hence, we reviewed the value and accuracy of radiomics for early non-invasive identification of Ki-67 levels and histological subtypes in lung cancer. Methods: PubMed, Cochrane, Embase, and Web of Science were comprehensively searched till 10 December 2023, using the Radiomics Risk of Bias Assessment Tool. Subgroup analyses of modeling variables were performed. Results: Thirty-three papers were finally included, with 13 for identifying adenocarcinoma and squamous, and 12 for identifying different pathotypes. In the validation set of the dichotomous task, the meta-analysis results for discriminating high Ki-67 levels yielded 0.77 c-index (95% CI: 0.74-0.79), 0.75 sensitivity (95% CI: 0.70-0.79), and 0.74 specificity (95% CI: 0.70-0.78). The validation set analysis in discriminating lung adenocarcinoma from squamous cell carcinoma yielded 0.78 c-index (95% CI: 0.76-0.80), 0.78 sensitivity (95% CI: 0.70-0.84), and 0.79 specificity (95% CI: 0.73-0.85). Conclusion: Radiomics is tool for non-invasively identifying high Ki-67 levels in lung cancer and identifying different subtypes. However, this is based on limited evidence with a high risk of bias in a subset of studies where radiomics has been performed. Therefore, more studies with larger samples are required to validate the results and develop intelligent readable tools.
No takes yet. Share an insight, caveat, or question.
Ziya Zhao (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: